Innovation And IntegrationAllurion is expanding its portfolio with the launch of AllurionMeds, integrating affordable GLP-1 weight loss medications into its AI-driven virtual platform, strengthening the company’s U.S. presence by addressing key obesity challenges.
Market Expansion And GrowthALUR's robust business model, with strong double-digit annual procedure growth and expansion into over 50 countries, represents 40% of the global population with a BMI of 25 or more.
Product Safety And EfficacyALUR's device had an impressively low rate of serious adverse events, at 3.1%, which is the lowest SAE rate reported in a pivotal FDA trial of a liquid-filled IGB for weight loss.